TAK
TAKEDA Terminates Phase 3 Soticlestat Study in Dravet and Lennox-Gastaut
Takeda has halted a Phase 3 trial of soticlestat in epilepsy patients previously exposed to fenfluramine, citing a business decision unrelated to patient safety.
Clinical
NVO
NOVO NORDISK Completes Phase 3 Trial of CagriSema Against Tirzepatide
The Danish drugmaker's head-to-head Phase 3 study of CagriSema versus Eli Lilly's tirzepatide in type 2 diabetes is now listed as completed.
Clinical
Spectrum Pharmaceuticals Suspends Phase 3 Poziotinib Trial in HER2 NSCLC
The registry entry for the poziotinib study in HER2 exon 20-mutated lung cancer now reads SUSPENDED, with no patients enrolled and a redesign under discussion with the FDA.
HRMY
Harmony Biosciences Completes Phase 3 Cannabidiol Trial in Fragile X
The registry entry for Harmony's Phase 3 study of cannabidiol in Fragile X syndrome now shows a status of COMPLETED, updated 1 September 2026.
Clinical
PDS Biotechnology Terminates Phase 3 Trial of PDS0101 in HPV16+ Head and Neck Cancer
PDS Biotechnology has terminated its Phase 3 study of PDS0101 plus pembrolizumab, citing financial constraints rather than safety concerns.
INCY
Incyte's Phase 3 Retifanlimab Anal Cancer Trial Listed as Completed
The POD1UM-303/InterAACT 2 study of retifanlimab added to carboplatin-paclitaxel in advanced anal cancer now carries COMPLETED status on ClinicalTrials.gov.